Board has approved unaudited financial results for first quarter ending 30, June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Concord Drugs Ltd has approved the unaudited financial results for the first quarter of FY26 ending June 30, 2025. This is a routine quarterly compliance filing under SEBI's listing requirements. The filing itself does not disclose specific revenue, profit, or margin figures — those would be detailed in the accompanying financial results document. As the results are unaudited, they have not yet been reviewed by statutory auditors. Investors will need to refer to the full results PDF or the company's website for line-item details such as revenue, PAT, expenses, and segment performance.
A standard quarterly results approval is a compliance event and typically has no immediate price impact on its own. The actual market reaction will depend on the numbers in the results — whether revenue and profit beat, meet, or miss street expectations.